Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia
- PMID: 12928714
- DOI: 10.1272/jnms.70.334
Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia
Abstract
Previously, we reported that morning bright light therapy improved sleep time and cognitive function in Alzheimer type of dementia. We conducted a double blind study to examine the effects of melatonin on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type of dementia. The subjects were 9 persons given a placebo (PLA), and 11 given melatonin ( 3 mg)(MLT). The mean age was 79.2+/-6.4 (17 females and 3 males). The drugs were given at 20: 30 each day for 4 weeks. We checked sleep time and activity by Actigraph through one week before and the 4th week after drug administration. Cognitive and non-cognitive functions were evaluated with the clinical dementia rating scale (CDR), and Mini Mental State Examination (MMSE), and the Alzheimer's Disease Assessment Scale (ADAS). We successfully recorded Actigraph data from 18 patients (PLA8, MLT10). The mean sleep time change ratio and SD of the administration of PLA in the night was-0.2+/-13.7%, and MLT was 33.2+/-37.6%. The mean activity counts and SD of the administration of PLA in the night was 29.8+/-77.0%; in MLT it was-44.9+/-21.9%. Melatonin significantly prolonged the sleep time (p=0.017) and decreased activity (p=0.014) in the night (21: 00-6: 00) in the MLT group, although no significant difference in sleep time or activity in the daytime (6: 00-21: 00) was recognized between the two groups. In comparison with ADAS cognition score changes, the mean change and SD in the PLA was 0.3+/-3.7; in MLT it was-4.3+/-3.6 points. In comparison with ADAS non-cognition score, the mean change and SD in the PLA group was-0.8+/-1.0, in the MLT group it was-4.1+/-2.2 points. There were also significant differences between the PLA and the MLT groups in the comparison with the score improvement of ADAS cognition (p=0.017) and non-cognition (p=0.002), otherwise there was no significant difference in improvement of MMSE between both groups. Melatonin administration had effect to improve sleep time and night activity, but no significant effect to improve daytime naps and activity. Although melatonin administration might has less strong effect on circadian rhythm than morning bright light therapy we previously reported, cognitive and non-cognitive functions were improved. Melatonin seemed to be useful for care of the Alzheimer type of dementia patients.
Similar articles
-
[Effects of bright light on cognitive disturbances in Alzheimer-type dementia].Nihon Ika Daigaku Zasshi. 1999 Aug;66(4):229-38. doi: 10.1272/jnms.66.229. Nihon Ika Daigaku Zasshi. 1999. PMID: 10466338 Japanese.
-
Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial.J Prev Alzheimers Dis. 2021;8(1):7-18. doi: 10.14283/jpad.2020.69. J Prev Alzheimers Dis. 2021. PMID: 33336219 Clinical Trial.
-
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.JAMA. 2008 Jun 11;299(22):2642-55. doi: 10.1001/jama.299.22.2642. JAMA. 2008. PMID: 18544724 Clinical Trial.
-
The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer's disease.Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):80-90. doi: 10.2174/187221411799015354. Recent Pat Endocr Metab Immune Drug Discov. 2011. PMID: 22074583 Review.
-
[Effects of melatonin on circadian time keeping system].Nihon Rinsho. 1998 Feb;56(2):302-7. Nihon Rinsho. 1998. PMID: 9503826 Review. Japanese.
Cited by
-
Melatonin attenuates cerebral hypoperfusion-induced hippocampal damage and memory deficits in rats by suppressing TRPM7 channels.Saudi J Biol Sci. 2022 Apr;29(4):2958-2968. doi: 10.1016/j.sjbs.2022.01.018. Epub 2022 Jan 18. Saudi J Biol Sci. 2022. PMID: 35531206 Free PMC article.
-
Role of immune-pineal axis in neurodegenerative diseases, unraveling novel hybrid dark hormone therapies.Heliyon. 2019 Feb 1;5(1):e01190. doi: 10.1016/j.heliyon.2019.e01190. eCollection 2019 Jan. Heliyon. 2019. PMID: 30775579 Free PMC article. Review.
-
Melatonin for Treatment-Seeking Alcohol Use Disorder patients with sleeping problems: A randomized clinical pilot trial.Sci Rep. 2020 May 26;10(1):8739. doi: 10.1038/s41598-020-65166-y. Sci Rep. 2020. PMID: 32457492 Free PMC article. Clinical Trial.
-
Sundowning in Dementia: Clinical Relevance, Pathophysiological Determinants, and Therapeutic Approaches.Front Med (Lausanne). 2016 Dec 27;3:73. doi: 10.3389/fmed.2016.00073. eCollection 2016. Front Med (Lausanne). 2016. PMID: 28083535 Free PMC article. Review.
-
Neurodegeneration and the Circadian Clock.Front Aging Neurosci. 2017 May 30;9:170. doi: 10.3389/fnagi.2017.00170. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28611660 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical